- A new preprint shared in Research Square analyzed the blood of people with post-vaccine syndrome (PVS). The small study evaluated 30 participants with PVS and compared them with controls using an advanced blood test technique. The researchers stated that post-vaccine syndrome is characterized by persistent immune dysregulation and issues with blood coagulation. “Our results highlight the complex interplay between immune activation, endothelial dysfunction, and coagulation pathologies in [PVS], while also highlighting distinct differences between these systems in Long COVID and [PVS],” the authors wrote.
- A drug called dapagliflozin, used to treat Type 2 Diabetes, is being investigated for Long COVID in a recently announced clinical trial. The trial, based in Ottawa, Canada, will enroll 192 people and administer 10 mg of the drug or a placebo daily for 12 months. Researchers stated the trial will take three years to complete, including follow-up. Contact: Poppy MacPhee, pmacphee@ottawaheart.ca.
- A double-blind clinical trial is evaluating an experimental drug called REGN7544 for people with postural orthostatic tachycardia syndrome (POTS), a form of dysautonomia that can overlap with Long COVID. The trial is enrolling 81 participants to test the drug, an NPR1 antagonist monoclonal antibody. The study has site locations in Arizona, California, Connecticut, Florida, Indiana, New York, Oklahoma, Tennessee, Utah, and Alberta, Canada. The study requires numerous in-person visits. Contact: clinicaltrials@regeneron.com.
